Opinion on Pharmaceuticals in North America

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Amgen: Vectibix disappoints in colorectal cancer but hope remains

Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.

Published By Datamonitor
06 Nov 2009
Expert View
Expert View

Amylin's choice of ally for exenatide will be crucial in the wake of its split from Lilly

Having announced an end to its co-development and marketing deal with Eli Lilly covering exenatide antidiabetic products, Amylin is now looking for a bigger partner to drive sales of Byetta and the new once-weekly formulation Bydureon. Datamonitor believes that several major pharmaceutical players meet the criteria to become a suitable ally for the company in its ongoing development of exenatide.

Published By Datamonitor
11 Nov 2011
CommentWire
CommentWire

Amylin: Byetta sales set for bumpy ride

Given that physicians expect to increase their use of Amylin's diabetes drug Byetta over the next two years, the product is expected to generate US sales of $336.1 million in 2006 and $555 million in 2007. However, oral rivals look set to take market share from Byetta thereafter, before a once-weekly formulation of the drug, expected in 2009 or later, can help the franchise recover.

Published By Datamonitor
13 Apr 2006
CommentWire
CommentWire

Andrx/Genpharm/Schwarz: three-way deal to hurt AstraZeneca

Following FDA approval of Schwarz's generic Prilosec, the company has allied with Andrx and Genpharm to market it. The deal, which combines Schwarz's court victory with Andrx/Genpharm's regulatory exclusivity, should bring significant revenue to all three. AstraZeneca, which made $4.5 billion from Prilosec in the US last year, is the only loser.

Published By Datamonitor
07 Nov 2002
CommentWire
CommentWire

Andrx: down but not out on Prilosec ruling

The Prilosec infringement decision is a heavy short-term blow for Andrx, particularly as KUDCO's version of the drug was ruled acceptable. However, it does not drastically affect the company's long-term prospects, which are based on its expertise in specialty generics. Even without omeprazole, Andrx should still be one of the fastest growing generics companies to 2007.

Published By Datamonitor
16 Oct 2002
CommentWire
CommentWire

Anti-TNFs: FDA calls for additional warnings on blockbuster class

Due to heightened concerns over a side effect that can leave users prone to infection, the FDA has flexed its new powers to impose safety warnings on anti-TNF drugs. However, Datamonitor believes that while this action may raise awareness of the side effect, it will not affect drug uptake in the many patients with autoimmune diseases that find relief in these therapies.

Published By Datamonitor
05 Sep 2008
ResearchWire
ResearchWire

Antiarrhythmics market: new product launches to reinvigorate growth

Published By Datamonitor
21 Jul 2006
CommentWire
CommentWire

Antibiotics: use drops among US children

A new study has reported a substantial decrease in pediatric antibiotic prescriptions between 1996 and 2000. The development shows the success of a wider campaign to reduce overuse of antibiotics - a serious problem that contributes to the development of disease-resistant forms of common bacteria.

Published By Datamonitor
04 Sep 2003
CommentWire
CommentWire

Antidepressants: FDA research may lead to adult warnings

The Food and Drug Administration (FDA) is set to examine the potential link between antidepressants and increased suicidal tendencies in adults. Even if the FDA finds such a link however, the likely outcome will be proposals for more 'black box' labels and its ultimate impact on antidepressant revenues will be relatively slight.

Published By Datamonitor
01 Oct 2004
ResearchWire
ResearchWire

Antihypertensives: ARBs at the heart of the market

Published By Datamonitor
27 Mar 2006

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.